Advanced Accelerator Applications S.A.
We are an innovative radiopharmaceutical company that develops, produces and commercializes MNM products. MNM is a medical specialty that uses trace amounts of radioactive compounds to treat diseases such as cancer and create functional images of organs and lesions. Our lead therapeutic product candidate, Lutathera, is a novel MNM compound that we are currently developing for the treatment of NETs, a significant unmet medical need. Lutathera is a Lu-177 labeled somatostatin analogue peptide that has received orphan drug designation from the EMA and FDA.
|Address||20 rue Diesel, 01630 Saint Genis Pouilly, France|
|Phone Number||+33 (0) 4 50 99 30 70|
|View Prospectus:||Advanced Accelerator Applications S.A.|
|Revenues||$86.6 mil (last 12 months)|
|Net Income||$-17.8 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$75.0 mil|
|Manager / Joint Managers||Citigroup/ Jefferies |
|CO-Managers||Canaccord Genuity/ JMP Securities |
|Expected To Trade:||11/11/2015|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|